
Index

- Access to Work scheme 50
- accountability, and self-medication
138–9
- acetaminophen (paracetamol) 65–6, 211
- acquired immune deficiency syndrome
(AIDS) 181
- activities of daily living (ADLs) 47
- acupuncture 142
- acute myeloid leukaemia 206
- acute phase reactants 184
- adalimumab 97, 101, 107–13
- adherence with drug therapy
and confusion 216
and education 254, 271
empowerment of patient 168
gout 131
nurse–patient relationship 165
and patient education 272–3
philosophy of rheumatology nursing
166
self-medication 136, 137
- adolescents, impact of arthritis 47
in parent 51
- adrenaline 65
- advice lines 166–7, 172, 231
- age factors
fibromyalgia syndrome 33
inflammatory muscle disease 41
osteoarthritis 30
polymyalgia rheumatica 21
Reiter's syndrome 24
rheumatoid arthritis 12
scleroderma 37
- age range, and patient education 255
- agranulocytosis 181
dapsone 207
sulfasalazine 195
- AIDS 181
- albuminuria 186
- alcohol intake
- anaemia 178
leflunomide 209, 210
methotrexate 169, 196
mycophenolate mofetil 210
osteoporosis 228
- aldosterone 65
- alendronate sodium 225–6
- alkaline phosphatase 181, 182
- alkylating agents 90
- allergic reactions 9
anakinra 105
anti-TNF α 108
- allodynia 64
- allopurinol 131
and azathioprine 201
and cyclophosphamide 203
gout 130
- alopecia 176, 202
- alternative medicine *see* complementary
medicine
- amitriptyline 71
- amyloidosis 182, 205
- anaemia
diet 140
gold (myocrisin) therapy 189
investigations 178
leucopenia 180
methotrexate 197
penicillamine 193
phenylbutazone 207
rheumatoid arthritis 16
urobilinogen 186
vitamin B12 177
- anakinra 96, 101, 104–6
allergic response 108
- anatomy of musculoskeletal system 5–8
in inflammatory arthritis 9–12
- ankylosing spondylitis (AS) 22
anti-TNF α 107, 114, 115
assessment 23
education 256

- ankylosing spondylitis (AS) (*Continued*)
 erythrocyte sedimentation rate 184
 management 23
 phenylbutazone 90, 206
 pregnancy 213
 symptoms 22
- anorexia
 drug monitor clinic protocols 175
 penicillamine 192
 urinalysis 185
- antibiotic therapy
 reactive arthritis 30
 septic arthritis 27, 28
- antibodies 94
- anti-cluster differentiation 20 (CD 20) B
 cell depletion 92, 116–19
- antidepressant drugs 71
- anti-interleukin 1 receptor antagonist
 (IL-1ra) 92, 104–6
- anti-malarials 83–5
- anti-nuclear antibody (ANA) 183
- anti-tumour necrosis factor alpha
 (anti-TNF α) 92, 107, 112–19
 and anakinra 105
 ankylosing spondylitis 23
 immunization 112
 mode of action 107–8
 pregnancy and breastfeeding 111–12
 psoriatic arthritis 26
 side effects 108–11
- anxiety 47
 in spouse 51
- aplastic anaemia
 gold (myocrisin) therapy 189
 leucopenia 180
 penicillamine 193
 phenylbutazone 207
- aromatherapy 142
- arthralgia 3
- arthritis mutilans 25
- Arthritis Self-Management Programme
 (ASMP) 249, 256, 262–3
- aspirin 75, 76, 78, 79
 and methotrexate 197
 pregnancy 213
- atherosclerosis 125
- audiocassettes for patient education 270
- auranofin 87, 189–90, 213
- autoantibodies 109, 116, 118
- autoimmune disorders 193
- autoimmunity 93
- azapropazone 73, 77, 80
- azathioprine 88
 contraception 214
 and corticosteroids 121, 123
 and mycophenolate mofetil 211
 pregnancy 213
 reactive arthritis 30
 surveillance 198–9
 vaccination 212
- baclofen 80
- basophils 179
- Behçet's disease 203
- beliefs, and philosophy of rheumatology
 nursing
 relating to environment 167
 relating to nursing 168
 relating to patient 167–8
- Bence Jones protein 182
- benzbromarone 131
- biochemical investigations 181–82
- biologically engineered therapies
 (biologics) 93
- biologic therapies 92
 adverse reactions 95–103, 108–11
 anti-TNF α 107–11, 112–19
 biologically engineered therapies 93
 classifications 93–4
 immunisation 112
 mode of action 94–5, 107–8
 pregnancy and breastfeeding 111–12
 treatment options 104–7
- bisphosphonates 225, 226
- blood disorders
 anakinra 105
 sodium aurothiomalate 233–4
 urinalysis 186
- blood monitoring, anti-TNF α 109
- blood pressure recording 176
- B lymphocytes 180
- bone, anatomy and physiology 5
- bone marrow suppression 205
- bone metabolism
 corticosteroids 124–5
 investigations 182

- bottom up approach, pain 64
- bowel associated arthritis 22
- brain, role in pain 64
- breastfeeding 212, 213, 214
 - anakinra 106
 - anti-TNF α 111–12, 118–19
- British Health Professionals in Rheumatology 171
- British Society of Rheumatology 171
- bronchiolitis obliterans 193
- brufen 80
- buprenorphine 68
- bursae 6–7
- bursitis 16
- Butacote *see* phenylbutazone

- caeruloplasmin 184
- calcinosis 43, 226
- calcitriol 227
- calcium
 - excretion 124
 - gastrointestinal absorption of 124
 - investigations 182
 - supplementation 226–7
- Caplan's syndrome 189
- capsaicin 145
- cardiovascular system
 - anti-TNF α 109–10, 117
 - NSAIDs 78
 - phenylbutazone 207
- caring 166
- cartilage 6
- cassettes for patient
 - education 270
- CDs for patient education 270
- celecoxib 75–6
- cell-mediated immune reactions 9
- central nervous system
 - NSAIDs 78
 - phenylbutazone 206
 - sulfasalazine 194
- cervicitis 30
- change, readiness for 271–72
- chemokines 95
- children
 - impact of arthritis 47, 48–9
 - inflammatory muscle disease 41
 - of parents with arthritis 51
 - septic arthritis 26, 27
 - see also* juvenile idiopathic arthritis
- chlorambucil 90, 205–6, 214
- chloroquine sulfate 83–5
- cholestyramine 209
- chondroitin sulfate 143
- chronic disease self-management
 - programme (CDSMP) 263
- ciclosporin 89–90
 - and colchicine 129
 - drug monitor clinic protocols 176
 - pregnancy 213
 - surveillance 203–5
 - vaccination 212
- circulation 7
- classification of rheumatic diseases 2
- clinical management plans (CMPs) 133, 134, 135
- clopromazine 68
- co-codamol 66
- codaprin 66
- codeine phosphate 67
- codydramol 66
- colchicine 128–9, 203
- collagenosis 123
- combination therapy 82
- communication between patient and physician 168–9
- community clinics 218–19
 - evaluation 219–20
- community drug monitoring 216–18
- community team 231
 - juvenile idiopathic arthritis 21
 - role in drug therapy 214–16
- compact bone 5
- compact discs for patient
 - education 270
- complementary medicine 139
 - acupuncture 142
 - aromatherapy 142
 - diet 140–1
 - herbal medicine 142–3
 - holism 143
 - massage 141
 - naturopathy 143
 - reflexology 142

- compound analgesia 66
- computer programs
 - for drug monitoring 172, 217
 - for patient education 270
- confusion, minimizing 215–16
- conjunctivitis 24
- connective tissue disease 34
 - chlorambucil 90, 205, 206
 - erythrocyte sedimentation rate 184
 - extractable nuclear antigen 183
 - gammaglobulin 183
 - renal function 182
- contraception 214
- contracting, in patient
 - education 260–1
- coping strategies 246
- corticosteroids 119, 123
 - adverse effects 121–3
 - atherosclerosis 125
 - bone mineral metabolism 124–5
 - dose reduction 125
 - glucocorticoids 120
 - half life 121
 - intra-articular/soft tissue
 - injections of 126
 - intramuscular 126
 - peptic ulceration 125
 - pregnancy 211
 - psoriatic arthritis 26
 - pulsed 125–6
 - reactive arthritis 30
 - rheumatic arthritis 120–1
 - septic arthritis 26, 28
 - sparing agents 121
 - vaccination 212
- cortisol 65
- costs of patient education 269
- C-reactive protein (CRP) 184
- creatinine 182
- CREST syndrome 39
- cyanocobalamin (vitamin B12) 177
- cyclo-oxygenase-2 (COX-2) inhibitors 75–6
- cyclophosphamide 89
 - contraception 214
 - as corticosteroid sparing agent 121
 - drug monitor clinic protocols 176
 - pregnancy 213
 - surveillance 201–203
 - vaccination 212
- cystitis, haemorrhagic 202
- cytokines 93, 94–5
- cytotoxic reactions 9
- dactylitis 24
- dapsone 91, 206–7
- demographic considerations, patient
 - education 255
- Depomedrone *see* methylprednisolone
- depression 47, 52–3
 - antidepressant drugs 71
 - in spouse 51
- dermatitis 188
- dermatomyositis
 - corticosteroids 123
 - inflammatory muscle disease
 - 41, 42–3
 - penicillamine 193–4
- dextromoramide 68
- dextropropoxyphene hydrochloride 67–8
- diabetes 201
- diagnosis
 - impact of 47
 - and patient education 256
- diamorphine hydrochloride 68–9
- diarrhoea 209
- diclofenac 77, 78, 80, 205
- diet
 - complementary medicine 140–1
 - gout 131
 - osteoporosis prevention 228
 - susceptibility to disease 11
- diffuse scleroderma 39
- diflunisal 78
- dihydrocodeine tartrate 67
- diltiazem 205
- disability 45, 46
- discharge planning, and self-medication 137
- disease duration, and patient
 - education 255
- disease-modifying anti-rheumatic drugs (DMARDs) 92, 167, 166
 - anti-malarials 83–5
 - and biologic therapies 101, 102
 - anti-TNF α 109, 110, 112

- combination therapy 82
- commencement 169–77
- documentation 172
- early treatment of rheumatoid arthritis
 - 81–2
- education 259
- empowerment of patient 168
- leucopenia 179, 180
- and memory failure 258
- mode of action and pharmacokinetics
 - 82–3, 94
- monitoring clinics 170–72
- patient preparation 169–71
- pregnancy 212, 213
- protocols, use of 172–7
- reactive arthritis 30
- rheumatoid nodules 16
- use of 81
- see also specific drugs*
- Distamine *see*
 - penicillamine/D-penicillamine
- documentation
 - community drug monitoring 217
 - drug monitoring 172
 - urine testing 186
- doloxene 68
- dothiepin 71
- D-penicillamine *see*
 - penicillamine/D-penicillamine
- drug monitoring clinics 170–72
 - protocols 174–7
- dual energy X-ray absorptiometry (DEXA), osteoporosis 224
- duration of disease, and patient
 - education 255
- Durogesic 69
- dyspepsia 175
- dysphagia 43
- dyspnoea 43, 193

- early morning stiffness (EMS) 16
- education 273–4
 - and adherence 272–3
 - aids 267–70
 - Arthritis Self-Management Programme 262–3
 - coverage 263–7
 - definitions 243–4
 - group 261–62
 - impact of arthritis 47, 48–9
 - individual 257–61
 - juvenile idiopathic arthritis 21
 - limitations 251–52
 - methotrexate information
 - sheet 274–6
 - monitoring clinics 171
 - nurse-led community clinics 221
 - nurse's role 252–4
 - opportunity 262
 - optimum timing 271–72
 - planning 254–7
 - purpose 250–51
 - by rheumatology nurse specialists
 - 230–31
 - self-medication 136, 137, 138
 - and severity of disease 49
 - and susceptibility to disease 11
 - useful theories and models
 - 244–50
- elderly patients
 - NSAIDs 76
 - self-medication 137
- electrophoresis 183
- employment, impact of arthritis 46, 49–50
- empowerment role of nurse in drug therapy 168–9
- Enbrel *see* etanercept
- Endoxana *see* cyclophosphamide
- enkephalin 62
- entheses 6
- enthesitis-related arthritis 20
- enthesopathy 22
- environmental factors, susceptibility to
 - disease 10, 11
- eosinophilia 188, 233
- eosinophils 180
- epidemiology of rheumatological
 - conditions 4
- erythrocyte sedimentation rate (ESR) 183–4
- etanercept 98, 101, 107–12, 113–14
- ethnic factors *see* racial factors
- etidronate 225
- exercise, and osteoporosis 228
- exfoliative dermatitis 195

- extended nurse prescribers (ENPs)
 - formulary 132, 133, 134
- extractable nuclear antigen (ENA) 183

- falls, and osteoporosis 228
- family relationships, impact of
 - arthritis 50–1
- fatigue 16, 49
- features of rheumatic diseases
 - 2–3
- Felty's syndrome
 - hepatic function 181
 - leucopenia 179, 180
 - thrombocytopenia 181
- fenbrufen 79
- fenopropfen 78, 80
- fentanyl 69
- fertility problems
 - chlorambucil 206
 - cyclophosphamide 203
 - sulfasalazine 196
- fibrinogen 184
- fibrocartilage 6
- fibromyalgia syndrome 32
 - diagnosis 32–3
 - induction and perpetuation
 - mechanisms 32
 - management 34
 - massage 141
 - symptoms 33
- financial impact of arthritis 48
- fish oils 140–1
- fluoride 226
- fluoxetine 71
- folate
 - deficiency 178, 195
 - supplementation 196, 197, 199
- folic acid 178, 196, 197
- folinic acid rescue 199
- Forsteo 227
- Fosamax (alendronate sodium) 225–6
- function, loss of 3

- gastrointestinal disorders
 - azathioprine 200
 - drug monitor clinic protocols 175–6
 - leflunomide 209
 - methotrexate 197
 - phenylbutazone 206
 - sulfasalazine 194
- gastrointestinal tract, and NSAIDs 73, 77
- gate control theory of pain 62–3
- gender factors
 - fibromyalgia syndrome 32, 33
 - inflammatory muscle disease 41
 - juvenile idiopathic arthritis 20
 - osteoarthritis 30
 - Reiter's syndrome 24
 - rheumatoid arthritis 12, 13
 - scleroderma 37
 - susceptibility to disease 10
 - systemic lupus erythematosus 34
- general practice 219
- general practitioners, practice-based
 - monitoring concerns 218
- genetic factors
 - inflammatory muscle disease 42
 - psoriatic arthritis 25
 - rheumatic arthritis 12
 - scleroderma 37
- giant cell arteritis (temporal arteritis)
 - 21, 123
- glucocorticoids 117, 120
- glucosamine 143–5
- glucose
 - metabolism 122–3
 - urinalysis 185
- glycosuria 175
- gold therapy 86, 87
 - anaemia 178
 - eosinophilia 180
 - needle phobia 258
 - pregnancy 213
 - proteinuria 186
 - surveillance 187–90
 - vaccination 212
 - see also* auranofin; sodium aurothiomalate
- Goodpasture's syndrome 193
- gout 126
 - clinical features 127
 - diagnosis 127–8
 - diet and lifestyle 131, 141
 - erythrocyte sedimentation rate 184
 - hyperuricaemia 126–7
 - precipitating factors 127

- prevalence 127
- treatment 128–31
- green-lipped mussel extract 140
- group education 261–63
- growth retardation, corticosteroid therapy 124
- haematological disorders
 - azathioprine 200
 - cyclophosphamide 203
 - dapsone 208
 - gold (myocrisin) therapy 188–9
 - leflunomide 210–11
 - methotrexate 197–8
 - penicillamine 192–3
 - phenylbutazone 207
 - rituximab 117
 - sodium aurothiomalate 233–4
 - sulfasalazine 195–6
- haematological investigations 177–81
- haematological reactions, NSAIDs 79
- haematuria
 - drug monitor clinic protocols 175, 176
 - penicillamine 193
 - urinalysis 186
- haemolytic anaemia 186
- haemorrhagic cystitis 202
- headaches 176, 194
- health, philosophy of rheumatology
 - nursing 166–7
- health belief model 246–7
- hepatic function 181
- hepatic problems, phenylbutazone 207
- hepatoglobin 184
- hepatotoxicity
 - azathioprine 200
 - ciclosporin 205
 - leflunomide 210
 - methotrexate 198
 - sulfasalazine 196
- herbal medicine 142–3
- herpes zoster
 - cyclophosphamide 202
 - drug monitor clinic protocols 176
 - methotrexate 198
- high efficacy opioids 68–71
- HIV 111
- Hodgkin's disease 181
- holism 143
- hormonal factors
 - rheumatoid arthritis 13
 - susceptibility to disease 10
- hormone replacement therapy (HRT) 224
- human immunodeficiency virus (HIV) 111
- Humira *see* adalimumab
- hyaline articular cartilage 6
- hyaluronans 143
- hydrocortisone 65
- hydroxychloroquine 213
- hydroxychloroquine sulfate 83–5
- hyperalgesia 64
 - fibromyalgia syndrome 33
 - methotrexate 198
 - sulfasalazine 195
- hypersensitivity 201
- hypersensitivity pneumoconitis 189
- hypertension
 - ciclosporin 204
 - leflunomide 210
- hyperuricaemia 126–7
- ibuprofen 77, 78, 79
 - education 256
 - and methotrexate 197
- immune complexes 9
- immune system 121
- immunization 212
 - anakinra 106
 - anti-TNF α 112, 119
- immunoglobulins 93–4
 - biologic therapies 94
 - investigations 181
 - rituximab 117
- immunopathogenic mechanisms 9–10
- immunosuppressive therapy 26
- impact of rheumatological conditions
 - 45–6
 - depression 52–3
 - educational 48–9
 - employment 49–50
 - family relationships 50–1
 - financial 48
 - personal 47–8
 - social 50–2

- Imuran *see* azathioprine
- incidence
- definition 4
 - inflammatory muscle disease 41
 - rheumatoid arthritis 12
- independent nurse prescribing 131, 132–3
- individual patient education 257–61
- indomethacin 77, 78, 79, 80
- Indomethian 72
- infections
- anakinra 105–6
 - anti-TNF α 110–11, 118
 - cyclophosphamide 202
 - methotrexate 198
- infective arthritis 184
- infertility
- chlorambucil 206
 - cyclophosphamide 203
 - sulfasalazine 196
- inflammation
- erythrocyte sedimentation rate 183–4
 - gold (myocrisin) therapy 189
 - leucocytes 178
- inflammation lung reactions 189
- inflammatory arthritis 9–12
- inflammatory cascade 10
- biologic therapies 94
- inflammatory eye disorders 205
- inflammatory muscle disease (polymyositis)
- clinical features 41, 42–4
 - corticosteroids 123
 - definition 41
 - disability 45
 - environmental factors 41
 - epidemiology 41
 - genetic factors 42
 - incidence 41
 - investigations 44–5
 - natural history 45
 - penicillamine 193–4
 - presentations 42
 - prognosis 45
 - survival 45
- infliximab 99, 107–12, 114–16
- combination therapy 88
 - infusion issues 101–2
- infusion issues, biologic therapies 101–3
- anti-TNF α 109, 115–16
- injection site reactions (ISRs), biologic therapies 105, 109
- innervation 8
- interactions between drugs
- azathioprine 200
 - biologic therapies 106, 118
 - ciclosporin 205
 - colchicine 129
 - cyclophosphamide 203
 - methotrexate 197
 - minocycline 208
 - NSAIDs 80
 - opioids 70
 - phenylbutazone 205
- interleukin-1 receptor antagonist 104–6
- International Classification of Functioning, Disability and Health (ICF) 46
- interstitial lung disease 210
- intra-articular injections
- corticosteroids 126
 - guidelines 146–8
 - monitoring clinics 172
- intra-articular pressure 8
- intramuscular injection
- corticosteroids 126
 - methylprednisolone 148–53
- intrinsic factor 177
- investigations
- biochemical 181–82
 - haematological 177–81
 - rheumatic disease activity 182–4
- iritis 23
- iron deficiency anaemia 16, 207
- itching 174
- joint involvement 3
- juvenile idiopathic arthritis (JIA) 19–21
- anti-TNF α 108
 - classification 19–20
 - education 272
- juvenile-onset adult rheumatoid arthritis 20

- ketones 186
- ketoacidosis 185
- ketoconazole 205
- ketoprofen 80
- kidney, and NSAIDs 77–8
- Kineret *see* anakinra
- lansoprazole 73
- latex agglutination test 183
- lay beliefs
 - and goal setting 171
 - nurse–patient relationship 167
 - philosophy of rheumatology nursing 167
- learned helplessness theory 245
- learning environment 254–5
- leflunomide 88
 - contraception 214
 - drug monitor clinic protocols 176
 - pregnancy 213
 - surveillance 208–11
- leucocytes 178–81
 - urinary 186
- leucocytosis 179
- leucopenia 179, 179–81
 - methotrexate 197
 - sulfasalazine 195
- leukaemia 180
 - chlorambucil 206
 - cyclophosphamide 202
- lifestyle factors, gout 131
- ligaments 6
- limited scleroderma 39
- lithium 80
- liver, and NSAIDs 79
- low efficacy opioids 67–8
- lung disease 43
- lymphatics 7–8
- lymphocytes 180
- lymphomas
 - anakinra 106
 - anti-TNF α 111
 - azathioprine 200
- Mabthera *see* rituximab
- macrocytosis
 - azathioprine 200
 - cyclophosphamide 203
 - methotrexate 197–8
- macrophages 179
- main-en-lorgnette deformity 25
- malignancy
 - anakinra 106
 - anti-TNF α 111
 - chlorambucil 206
 - cyclophosphamide 202
- marital relationship, impact of
 - arthritis on 50
- massage 141
- mast cells 179
- mastery of skills 248–9
- mean cell volume (MCV) 195
- medication cards 215, 216
- memory failure, and patient
 - education 258
- Mesna 202
- metacarpophalangeal (MCP) joints 13,18
- metatarsophalangeal (MTP) joints 13,18
- methaemoglobin 196
- methotrexate 87
 - and alcohol 169, 196
 - anaemia 178
 - ankylosing spondylitis 23
 - and biologic therapies 92, 102, 109
 - adalimumab 113
 - anakinra 104, 106, 112
 - etanercept 113, 114
 - infliximab 114, 116
 - community drug monitoring 216, 217
 - contraception 214
 - and corticosteroids 121, 123
 - drug monitor clinic protocols 176
 - and hydroxychloroquine 83
 - and leflunomide 88, 209
 - needle phobia 258
 - and NSAIDs 80
 - nurse prescribing 135
 - patient information sheet 274–7
 - pregnancy 213
 - preparation of patient 170
 - psoriatic arthritis 26
 - reactive arthritis 30
 - rheumatoid nodules 16
 - surveillance 196–9
 - vaccination 212

- methylprednisolone
 - intramuscular injection 126, 148–53
 - case scenarios 152–3
 - patient information sheet 150–1
 - pulsed 123, 125–6
- metrology graphs 172
- metrology index 23
- middle aged adults, impact of arthritis 48
- minocycline (Minocin) 91, 208
- mixed educational ability, and patient education 256
- moclobemide 80
- modelling 249–50
- monitoring drugs
 - clinics 170–72
 - protocols 174–7
 - community drug monitoring 216–18
- monocytes 179
- morbidity 4
- morphine 69–70, 225
- mortality 4, 12
- motion 8
- mouth ulcers
 - azathioprine 200
 - cyclophosphamide 202
 - drug monitor clinic protocols 175
 - gold (myocrisin) therapy 188
 - methotrexate 197
 - penicillamine 192
- mucocutaneous reactions
 - gold (myocrisin) therapy 188
 - penicillamine 192
 - phenylbutazone 206
- mucous membranes 233
- multidisciplinary team 231
- mu receptors 69
- muscle 5
- musculoskeletal system, anatomy and physiology 5–8
 - in inflammatory arthritis 9–12
- myasthenia gravis 193
- mycophenate mofetil (MMF)
 - 91, 211, 213
- myeloma 184
- myocrisin 86, 187–90
- myositis 196, 201
- naproxen 77, 78, 79
- neuropathy 143
- nausea
 - cyclophosphamide 202
 - drug monitor clinic protocols 175
 - leflunomide 209
 - methotrexate 197
 - penicillamine 192
- neck instability 176
- needle phobia 258
- neoplasms 206
- nephrotic syndrome 193
- nephrotoxicity 187, 204
- neurokinin 64
- neurological effects, anti-TNF α 111
- neurotoxicity 189
- neutropenia
 - gold (myocrisin) therapy 188
 - mycophenolate mofetil 211
 - penicillamine 193
- neutrophils 179, 180
- nitrate, urinary 175, 186
- nitroid reactions 189
- N-methyl-D aspartate (NMDA) 64
- nociceptors 63–4
- non-compliance with treatment 169
- non-Hodgkin's lymphoma (NHL) 116, 117, 118, 200
- non-opioid analgesia 65–6
- non-steroidal anti-inflammatory drugs (NSAIDs) 71–2, 167
 - administration 73
 - choice 72–3
 - classification 72
 - cyclo-oxygenase-2 inhibitors 75–6
 - drug interactions 80
 - drug monitor clinic protocols 176
 - education 258, 259
 - gastrointestinal problems 73
 - glucosamine compared with 145
 - gout 130
 - hepatic function 181
 - indicators 73–4
 - and methotrexate 197
 - mode of action 74
 - pharmacokinetics 75
 - reactive arthritis 30

- septic arthritis 28
- side effects 76–9
- ulcerogenic properties 125
- nurse-led community clinics 220–21
- nurse–patient relationship 165–6, 166, 169
 - and self-medication 138
- nurse prescriber extended formulary 132, 133, 134
- nurse prescribing 131–2
 - educational preparation 134
 - evaluation 134–6
 - independent 132–3
 - professional responsibilities 134
 - supplementary 133–4
- nurse's role in drug therapy 168–9

- obliterative bronchiolitis 189
- occupational impact of rheumatological conditions 46, 49–50
- occupational therapists 215, 216
- oligoarthritis 20, 25
- oligoarticular onset juvenile idiopathic arthritis 20
- oligospermia 196
 - see also* infertility
- omeprazole 73
- opera-glass hands 25
- opioids 66–7
 - adverse effects 70
 - drug interactions 70
 - high efficacy 68–71
 - low efficacy 67–8
 - osteoporosis 225
- opportunity education 262
- osteoarthritis (OA) 30–2
 - biologic therapies 104
 - capsaicin 145
 - classification 31
 - diet 140, 141
 - education 256
 - glucosamine 144
 - and NSAIDs 74
 - vitamin supplements 140
- osteoblasts 124, 222
- osteoclasts 124, 222

- osteomalacia 182
- osteoporosis 222
 - classification 222–3
 - drugs to reduce fracture risk 225–8
 - hormone replacement therapy 224
 - investigations 224
 - pain management 225
 - prevention 228
 - risk factors for fracture 223–4
- outpatient appointments, new ways of utilizing 222
- oxyphenbutazone 79

- Paget's disease 182
- pain 3, 61–2
 - ankylosing spondylitis 22
 - brain's role 64
 - fibromyalgia syndrome 33
 - gate control theory 62–3
 - impact 49
 - osteoporosis 225
 - physiological effects of acute 64–5
 - physiology 62–3
 - polymyalgia rheumatica 21
 - receptors 63–4
 - rheumatoid arthritis 14, 16
- Palfium 68
- pancytopenia 198
- paracetamol 65–6, 213
- parathyroid hormone (PTH) 124, 227
- paroxetine 71
- patient education *see* education
- patient group directions (PGDs) 132
 - methylprednisolone injection 148–52
- patient-held booklets 217
- Patient Knowledge Questionnaire 259
- pemphigus 192, 193
- penicillamine/D-penicillamine 85–6
 - drug monitor clinic protocols 176
 - pregnancy 213
 - surveillance 191–94
 - urinalysis 185, 186
 - vaccination 212
- peptic ulceration 125
- pernicious anaemia 177
- personal impact of arthritis 47–8
- persuasion and self-efficacy 250
- pethidine hydrochloride 70

- pharmacists 215–16
- phenylbutazone 78, 79, 90–1
 - surveillance 206–7
- phenytoin 205
- philosophy of rheumatology nursing
 - 166–8
- phosphate investigations 182
- physical impact of rheumatological conditions 46
- physiological state, reinterpretation of 250
- physiology of musculoskeletal system
 - 5–8
 - in inflammatory arthritis 9–12
- physiotherapists 23
- pill dispensers 215
- piroxicam 73, 258
- plasma proteins 183
- plasma viscosity (PV) 184
- platelets 181
- pleural effusions 189
- pleurisy 189
- pneumoconiosis 189
- pneumonitis 198
- polyarteritis
 - haematuria 186
 - leucocytosis 179
 - proteinuria 186
- polyarteritis nodosa 201
- polyarthritides 20, 184
- polyarticular onset juvenile idiopathic arthritis 20
- polymyalgia rheumatica (PMR)
 - 21, 123, 184
- polymyositis *see* inflammatory muscle disease
- post-injection reactions, gold (myocrisin) therapy 189
- practice nurses 215
- prednisolone 120, 123
 - polymyalgia rheumatica 21
 - withdrawal syndrome 125
- preferences, and patient education
 - drug therapy 257–8
 - information transfer 259–60
- pregabalin 71
- pregnancy 212–14
 - biologic therapies
 - anakinra 106
 - anti-TNF α 111–12, 118–19
 - NSAIDs 79
 - rheumatoid arthritis 13
 - scleroderma 40
- preparation of patient for DMARDs
 - 169–70
- prevalence
 - definition 4
 - depression 53
 - estimates for selected rheumatological disorders 4
 - gout 127
 - juvenile idiopathic arthritis 19
 - rheumatoid arthritis 12
 - systemic lupus erythematosus 34
- primary healthcare team 215, 229
 - see also* community team
- primary osteoporosis 222
- probenecid 80, 130
- pro-drugs 75
- professional closeness 253–4
- prostacyclin 75
- prosthetic joints 26, 28
- protein pump inhibitors 73
- proteinuria 186
 - drug monitor clinic protocols 175, 176
 - gold (myocrisin) therapy 187
- Protelos (strontium ranelate) 227–8
- protocols, use of 172–7
- proximal interphalangeal (PIP) joints 13
- pruritis 188
- pseudogout 129–30
- psoriatic arthritis (PsA) 24–6
 - antimalarials 85
 - anti-TNF α 107, 113, 114, 115
 - azathioprine 199
 - ciclosporin 204
 - dapsone 91, 207
 - juvenile idiopathic arthritis 20
 - methotrexate 87, 196
- psychological impact of rheumatological conditions 46–7
- pulmonary arteritis 189
- pulmonary disorders
 - gold (myocrisin) therapy 189
 - penicillamine 193
 - sulfasalazine 195
- pulmonary fibrosis 203
- pulmonary toxicity 207

- pulsed corticosteroids 125–6
- purine metabolism disorders *see* gout
- pyramidal approach to rheumatoid arthritis
 - treatment 81
- pyrexia 195

- quality of information for patient
 - education 270
- quality of life, and rheumatoid arthritis 46

- racial factors
 - inflammatory muscle disease 41
 - osteoarthritis 30
 - systemic lupus erythematosus 34
- radiography, osteoporosis 224
- raloxifene 226
- rashes
 - dapsone 208
 - drug monitor clinic protocols 174
 - gold (myocrisin) therapy 188
 - leflunomide 210
 - methotrexate 197
 - penicillamine 192
 - sulfasalazine 195
- Raynaud's phenomenon 36, 37
- reactive arthritis 28–9
 - erythrocyte sedimentation rate 184
 - sulfasalazine 194
 - triggering factors 29–30
 - see also* Reiter's syndrome
- readability of educational documents 269
- readiness for change 271–72
- reading levels, and patient education 268
- reciprocity, and patient
 - education 252–3
- record keeping *see* documentation
- red blood cells (RBCs) 177
- referral to rheumatology nurse
 - specialists 230
- reflexology 142
- reinterpretation of physiological
 - state 250
- Reiter's syndrome 23–4, 28
 - management 24
 - symptoms 24
 - urinalysis 186
- Remicade *see* infliximab
- renal disorders
 - ciclosporin 204
 - gold (myocrisin) therapy 187
 - methotrexate 198
 - penicillamine 193
 - sodium aurothiomalate 234
- renal function 182
- respiratory reactions,
 - leflunomide 210
- respiratory system, and NSAIDs 79
- retinal toxicity, anti-malarials 84
- rheumatic disease activity, assessment of
 - 182–4
- rheumatoid arthritis (RA) 12–13
 - amyloidosis 182
 - anaemia 178
 - areas affected by 13–14
 - assessment of rheumatic disease activity
 - 182–4
 - biologic therapies 92
 - anakinra 106
 - anti-TNF α 107, 111, 113, 114, 117
 - classification 13, 15
 - community team 215
 - complementary medicine 139
 - aromatherapy 142
 - diet 140, 141
 - massage 141
 - reflexology 142
 - corticosteroids 120–1, 126
 - disability 46
 - DMARDs 81–2, 92
 - antimalarials 83
 - auranofin 190–2
 - azathioprine 88, 199, 200
 - chlorambucil 205, 206
 - ciclosporin 89, 203, 204
 - cyclophosphamide 89, 201
 - dapsone 91, 207
 - gold (myocrisin)
 - therapy 187, 189
 - leflunomide 209
 - methotrexate 87, 196
 - minocycline 91, 208
 - myocrisin 86
 - penicillamine 85–6, 191
 - sodium aurothiomalate 232–5

- rheumatoid arthritis (RA) (*Continued*)
- sulfasalazine 85, 194, 195
 - education 256, 259
 - and adherence 272, 273
 - empowerment of patient 169
 - erosions 18–19
 - extra-articular manifestations 16–17
 - general practice 219
 - hepatic function 180
 - impact 46, 47
 - depression 53
 - employment 49–50
 - leucocytosis 179
 - nurse prescribing 135
 - outpatient appointments 222
 - pain and stiffness 16
 - philosophy of rheumatology
 - nursing 167
 - pregnancy 212–14
 - progression 17–18
 - renal function 182
 - rheumatoid factor 14–15
 - self-medication 136
 - thrombocytosis 181
 - urinalysis 186
- rheumatoid factor (RF) 14–15
- eosinophilia 180
 - investigations 182–3
- rheumatological conditions 1–2
- classification 2
 - connective tissue disease 34
 - epidemiology 4
 - features 2–3
 - fibromyalgia syndrome 32–4
 - impact 45–53
 - inflammatory muscle disease (polymyositis) 41–5
 - juvenile idiopathic arthritis 19–21
 - musculoskeletal system in inflammatory arthritis 9–12
 - osteoarthritis 30–2
 - polymyalgia rheumatica 21
 - rheumatoid arthritis 12–19
 - scleroderma (systemic sclerosis) 36–40
 - septic arthritis 26–8
 - spondylitis-associated inflammatory arthritis 22
 - ankylosing spondylitis 22–3
 - Reiter's syndrome 23–4
 - psoriatic arthritis 24–6
 - reactive arthritis 28–30
 - systemic lupus erythematosus 34–6
- rheumatologists 214–15
- rheumatology nursing
- nature of 165–6, 229–32
 - philosophy of 166–8
 - referral to 230
- Ridula (auranofin) 87, 190–1, 213
- rifampicin 205
- risedronate 226
- risks of drug therapy, and patient education 266–7
- rituximab 100, 116–19
- infusion issues 101–2, 103
- rofecoxib 75
- Rose Waaler test (sheep cell agglutination test) 15, 183
- St John's wort 205
- Salazopyrin *see* sulfasalazine
- 'sausage digit', Reiter's syndrome 24
- scleroderma (systemic sclerosis) 36
- anti-nuclear antibody 183
 - classification 38–9
 - clinical features 36, 37
 - epidemiology 37
 - immunologic features 40
 - mycophenolate mofetil 211
 - penicillamine 191
 - skin involvement 38–9
 - systemic features 39–40
 - vascular abnormalities 37–8
- scleroderma renal crisis 40
- Seatone 140
- secondary osteoporosis 222–3
- second line therapies *see* disease-modifying anti-rheumatic drugs
- selective estrogen receptor modulators (SERMs) 226
- self-efficacy theory 247–50

- self-medication 136
 - advantages 137–8
 - case for 136–7
 - stages in implementation of 138–9
- septicaemia 202
- septic arthritis
 - definition 26
 - infection routes 27
 - investigation and diagnosis 27–8
 - leucocytosis 179
 - micro-organisms responsible for 27
 - presentation 26–7
 - treatment 28
- septic joint 176
- serotonin, and gate control theory of pain 62
- serotonin uptake inhibitors 71
- sertraline 71
- serum glutamic oxaloacetic transaminase (SGOT) 181
- shared care booklets 217
- shared goals, establishment in patient education 259
- sheep cell agglutination test (SCAT) 15, 183
- side effects of drugs, and patient education 258, 266–7
- sine scleroderma 39
- Sjögren's syndrome 183, 216, 258
- skin cancer 211
- skin problems
 - drug monitor clinic protocols 174
 - gold (myocrisin) therapy 188, 233
 - leflunomide 210
 - methotrexate 197
 - NSAIDs 79
 - penicillamine 192
 - sodium aurothiomalate 233
 - sulfasalazine 195
- skin thickening 38
- slow-acting anti-rheumatic drugs (SAARDs) *see* disease-modifying anti-rheumatic drugs
- smoking, and osteoporosis 228
- social impact of rheumatological conditions 46, 50–2
- social learning theory 247
- social support
 - benefits 51
 - costs of receiving 51
 - role 50
- socioeconomic factors
 - depression 47
 - susceptibility to disease 11
- sodium aurothiomalate 232–5
 - community drug monitoring 217
 - guidelines for nurses 216, 232–5
- soft tissue injections 126
- software
 - for community drug monitoring 217
 - for patient education 270
- specific gravity of urine 185
- spondylitis, inflammatory arthritis
 - associated with 22
 - see also* ankylosing spondylitis; psoriatic arthritis; reactive arthritis
- spouse, impact of arthritis on 50–1
- steroids *see* corticosteroids
- Stevens–Johnson syndrome 195, 210
- stiffness 3
 - ankylosing spondylitis 22
 - rheumatoid arthritis 14, 16
- Still, George Frederick 19
- Still's disease *see* juvenile idiopathic arthritis
- St John's Wort 205
- stress
 - occupational 49
 - in spouse 50–1
 - susceptibility to disease 11
- stress and coping theory 245–6
- strontium ranelate 227–8
- substance P 63, 145
- sulfasalazine 85
 - anaemia 178
 - ankylosing spondylitis 23
 - community drug monitoring 217
 - drug monitor clinic protocols 175, 176
 - pregnancy 213
 - surveillance 194–6
 - urinalysis 185
 - vaccination 212
- sulfapyridine 130–1
- sulindac 78
- supplementary nurse prescribing 131, 133–4

- support from rheumatology nurse
 - specialists 232
- supportive nursing 166
- surveillance, drugs requiring
 - auranofin therapy in RA 190–1
 - azathioprine 199–201
 - chlorambucil 205–6
 - ciclosporin 203–5
 - cyclophosphamide 201–203
 - dapsone 207–8
 - gold (myocrisin) therapy 187–90
 - leflunomide 208–11
 - methotrexate 196–9
 - minocycline 208
 - mycophenolate mofetil 210
 - penicillamine 191–94
 - phenylbutazone 206–7
 - sulfasalazine 194–6
- susceptibility to disease 10–11
- swelling 3
- symmetric polyarthritis 25
- synovial fluid 6
- synovial joints 7
- synovitis 11–12
 - monitoring clinics 171
- synovium 6
- systemic arthritis 19, 20–1
- systemic lupus erythematosus (SLE) 34
 - antimalarials 83
 - anti-nuclear antibody 183
 - corticosteroids 125
 - C-reactive protein 184
 - cyclophosphamide 89, 201
 - haematuria 186, 193
 - leucopenia 179, 180
 - mycophenolate mofetil 210
 - symptoms 35–6
- systemic sclerosis *see* scleroderma

- taste disturbance 192
- T cell receptors (TCRs) 109–110
- teaching aids 267–70
- teenagers, impact of arthritis 47
 - in parent 51
- telephone advice lines 165–6, 172, 231
- Temgesic 68
- temperature 8

- temporal arteritis (TA, giant cell arteritis)
 - 21, 123
- tendons 6
- tendon sheaths 6–7
- tenosynovitis 16
- tenoxicam 73
- teriparatide 227
- tetracycline 30
- thalamus 64
- therapeutic nursing 165–4
 - and patient education 252, 253
- therapeutic partnership 165–6, 168
 - continuation 171
 - and self-medication 138
- thrombocytopenia 181
 - gold (myocrisin) therapy 186
 - methotrexate 197
 - penicillamine 192
 - sulfasalazine 195
- thrombocytosis 181
- thromboxane 75
- tiaprofenic acid 78
- T lymphocytes 180
- top down approach, pain 64
- trabecular bone 5
- tramadol hydrochloride (Zydol)
 - 70–1
- transcutaneous electrical nerve stimulation (TENS) 63
- tricyclic drugs 71
- tuberculosis
 - anakinra 106
 - anti-TNF α 110–11, 112, 115
- tumour necrosis factor alpha (TNF α)
 - 107, 110
- type A beta fibres 63
- type A delta fibres 63
- type C fibres 63

- ulcerative stomatitis 210
- urea investigations 182
- urethritis 24, 30
- uricosuric drugs 130–1
- urinary problems 174–5
- urinary tract infections 186
- urine testing 184–6
- urobilinogen 186
- uveitis 23

- vaccination *see* immunization
- valdecoxib 76
- vasculitis
 - azathioprine 199
 - chlorambucil 205
 - corticosteroids 123
 - cyclophosphamide 201
 - methotrexate 196
 - mycophenolate mofetil 211
- vasomotor reactions 189
- venlafaxine 71
- veto-participation 169
- videotapes for patient education 270
- vitamin B12 177, 178
- vitamin C 140
- vitamin D 124, 227
- vitamin E 140
- vomiting
 - cyclophosphamide 202
 - methotrexate 197
- warfarin 201, 208
- washout procedure 209
- Wegener's granulomatosis 201
- weight loss 16
- Westergren method 184
- white blood cells (WBCs) 178–81
 - causes of low count 180–81
 - urinary 186
- written educational material 267–70
- X-rays, osteoporosis 224
- young adults, impact of arthritis on 48
- Zydol (tramadol hydrochloride) 70–1

